Corneal edema Market Analysis

Emerging therapies for corneal edema, including EO2002, TTHX1114, and others, are anticipated to drive growth in the corneal edema market over the coming years.

DelveInsight has released a new report titled “Corneal Edema – Market Insights, Epidemiology, and Market Forecast–2034”, offering a comprehensive overview of the condition, historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Corneal edema market report @ https://www.delveinsight.com/report-store/corneal-edema-us-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Corneal edema Market Report:

The corneal edema market is projected to witness steady growth over the forecast period (2023–2034), particularly in the United States, where expansion will be driven by the launch of new therapies. In 2022, the U.S. market—dominated by corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and other available treatments—generated approximately USD 489 million.

According to DelveInsight estimates, there were about 1,149,967 diagnosed prevalent cases of corneal edema in the U.S. in 2022, with numbers expected to rise throughout the forecast period. Market growth is anticipated to accelerate as innovative therapies such as EO2002 enter the landscape.

Recent regulatory milestones are further shaping the treatment outlook:

• April 2025: The FDA granted Fast Track designation to urcosimod (formerly OK-101) for neuropathic corneal pain, an indication with no currently approved therapies. The drug, a lipid-conjugated chemerin peptide agonist targeting ChemR23, showed encouraging results in a Phase 2 trial for dry eye disease.

• December 2024: Glaukos submitted a New Drug Application (NDA) for Epioxa, a non-invasive corneal cross-linking therapy that avoids epithelial removal. If approved, it would become the first FDA-approved treatment of its kind for corneal ectasia.

• June 2024: The FDA granted both Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations to AURN001, an allogeneic cell therapy for corneal edema secondary to endothelial disease. This one-time procedure, combining neltependocel (allogeneic human corneal endothelial cells) with a rho kinase inhibitor (Y-27632), demonstrated meaningful improvements in visual acuity in the Phase 1/2 CLARA trial, with the high-dose group achieving a statistically significant three-line gain over controls.

Several key players, including Emmetrope Ophthalmics (Emmecell), Trefoil Therapeutics, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Santen Pharmaceutical, Actual Eyes, and others, are actively advancing their pipelines to strengthen the treatment landscape.

Promising investigational therapies such as EO2002, TTHX1114, and additional novel candidates are expected to drive the next wave of innovation in the corneal edema market.

Corneal edema Overview

Corneal edema refers to the swelling of the cornea caused by an abnormal accumulation of fluid within the corneal layers. This fluid buildup disrupts the cornea’s normal transparency, leading to blurred or cloudy vision.

The condition typically results from endothelial cell dysfunction or damage, which impairs the cornea’s ability to pump out excess fluid. Common causes include:

• Fuchs’ endothelial dystrophy

• Ocular surgery complications (e.g., cataract surgery)

• Eye trauma or infection

• Prolonged contact lens wear

• Elevated intraocular pressure (glaucoma)

Corneal edema Market Outlook

The management of corneal edema is tailored according to its cause and severity. Initial therapy often involves hypertonic saline drops or ointments and topical corticosteroids to reduce inflammation and draw out excess corneal fluid. Hyperosmotic agents, including oral or topical carbonic anhydrase inhibitors, may also be prescribed. Bandage contact lenses can enhance vision by smoothing the corneal surface. When endothelial damage is extensive, surgical procedures such as corneal transplantation—most commonly Descemet’s Stripping Endothelial Keratoplasty (DSEK) or Descemet’s Membrane Endothelial Keratoplasty (DMEK)—may be required. In cases associated with secondary glaucoma, laser-based options like Selective Laser Trabeculoplasty (SLT) can be considered. Supportive measures include addressing underlying conditions and using artificial tears for ocular lubrication. The treatment landscape is continually advancing, with investigational therapies such as TTHX1114 and sirolimus showing potential to broaden future options for managing corneal edema.

Discover how the Corneal edema market is rising in the coming years @ https://www.delveinsight.com/sample-request/corneal-edema-us-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Corneal edema Emerging Drugs

• EO2002: Emmetrope Ophthalmics LLC

• TTHX1114: Trefoil Therapeutics

Scope of the Corneal edema Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Corneal edema Companies: Emmetrope Ophthalmics LLC (“Emmecell”), Trefoil Therapeutics, D. Western Therapeutics Institute (DWTI), Kowa Ltd., Santen Pharmaceutical, Actual Eyes, and others

• Key Corneal edema Therapies: EO2002, TTHX1114, and others

• Corneal edema Therapeutic Assessment: Corneal edema current marketed and Corneal edema emerging therapies

• Corneal edema Market Dynamics: Corneal edema market drivers and Corneal edema market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Corneal edema Unmet Needs, KOL’s views, Analyst’s views, Corneal edema Market Access and Reimbursement

To know what’s more in our Corneal edema report, visit https://www.delveinsight.com/report-store/corneal-edema-us-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Corneal edema Market Report:

1. Corneal edema market report covers a descriptive overview and comprehensive insight of the Corneal edema Epidemiology and Corneal edema market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

2. The Corneal edema market report provides insights into the current and emerging therapies.

3. The Corneal edema market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Corneal edema market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Corneal edema market.

Got queries? Click here to know more about the Corneal edema market Landscape

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Corneal edema Patient Share (%) Overview at a Glance

5. Corneal edema Market Overview at a Glance

6. Corneal edema Disease Background and Overview

7. Corneal edema Epidemiology and Patient Population

8. Country-Specific Patient Population of Corneal edema

9. Corneal edema Current Treatment and Medical Practices

10. Unmet Needs

11. Corneal edema Emerging Therapies

12. Corneal edema Market Outlook

13. Country-Wise Corneal edema Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Corneal edema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Corneal edema Market Outlook 2034

Related Reports:

Corneal edema Pipeline Insights, DelveInsight

“Corneal edema Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Corneal edema market. A detailed picture of the Corneal edema pipeline landscape is provided, which includes the disease overview and Corneal edema treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/